These TRE-MYC (TetO-c-Myc or Teto-MYC) hemizygous transgenic mice carry the human myelocytomatosis oncogene, MYC, regulated by a tetracycline operator (tetO). When mated to a mutant strain expressing tetracycline-controlled transactivator protein (tTA), expression of MYC protein may be regulated with tetracycline or its analog doxycycline (dox) in the double mutant offspring.These mice may be useful for studying tumor development and regression.
J Michael Bishop, UCSF School of Medicine
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Inducible, Inserted expressed sequence, Humanized sequence) |
Expression of MYC in these transgenic mice is regulated by a tetracycline operator (tetO). MYC is a transcription factor involved in cellular proliferation and differentiation, and is often upregulated in tumors, leukemias and lymphomas. Hemizygous mice are viable and fertile, homozygotes do not survive. When mated to a mutant strain expressing tetracycline-controlled transactivator protein (tTA), expression of MYC protein may be regulated with tetracycline or its analog doxycycline (dox) in the double mutant offspring.
When bred to B6.Cg-Tg(Cebpb-tTA)5Bjd/J mice (as Stock No. 003563) expressing tTA in liver, withdrawal of dox from double transgenic mice develop invasive metastatic liver tumors, and all mice die within 2 weeks onset. When doxycycline treatment is re-administered, rapid and sustained tumor regression is evident.
When bred to B6.Cg-Tg(Pax8-rtTA2S*M2)1Koes/J (see Stock No. 007176) expressing rtTA in renal tubular epithelial cells, induction of doxycycline causes polycystic kidneys, kidney failure and renal adenomas.
A transgenic vector was generated encoding the human myelocytomatosis viral oncogene cDNA (MYC) under control of a tetO promoter. The construct was microinjected into FVB/NJ fertilized oocytes, and mice from founder line 36a were bred to FVB/NJ mice for at least 10 generations to establish a colony. Upon arrival at The Jackson Laboratory Repository, mice were bred to FVB/NJ mice (as Stock No. 001800) for at least one generation.
Expressed Gene | MYC, MYC proto-oncogene, bHLH transcription factor, human |
---|---|
Site of Expression |
Allele Name | transgene insertion 36a, J Michael Bishop |
---|---|
Allele Type | Transgenic (Inducible, Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | TetO-c-Myc; Teto-MYC; Tg(tetO-MYC)36Bop; TRE-MYC |
Gene Symbol and Name | Tg(tetO-MYC)36aBop, transgene insertion 36a, J Michael Bishop |
Gene Synonym(s) | |
Promoter | tetO, tet operator, |
Expressed Gene | MYC, MYC proto-oncogene, bHLH transcription factor, human |
Strain of Origin | FVB/N |
Chromosome | UN |
General Note | Phenotypic Similarity to Human Syndrome: Renal Cell Carcinoma J:222943. |
Molecular Note | This transgene contains a human v-myc avian myelocytomatosis viral oncogene homolog cDNA and regulatory elements from the bacterial tetracycline-resistance operon. There are two founder #36 lines. Transgene insertions are on an autosomal chromosome in this line. |
Mutations Made By | J Michael Bishop, UCSF School of Medicine |
When maintaining a live colony, hemizygous mice may be bred to wildtype (non-carrier) mice from the colony or to FVB/NJ inbred mice (as Stock No. 001800). Homozygous mice do not survive.
When using the tet-o-MYC line 36 mouse strain in a publication, please cite the originating article(s) and include JAX stock #019376 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier forTg(tetO-MYC)36aBop |
Frozen Mouse Embryo | FVB/N-Tg(tetO-MYC)36aBop/J | $2595.00 |
Frozen Mouse Embryo | FVB/N-Tg(tetO-MYC)36aBop/J | $2595.00 |
Frozen Mouse Embryo | FVB/N-Tg(tetO-MYC)36aBop/J | $3373.50 |
Frozen Mouse Embryo | FVB/N-Tg(tetO-MYC)36aBop/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.